Welcome to our dedicated page for Visionary Holdings SEC filings (Ticker: GV), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The SEC filings page for Visionary Holdings Inc. (Nasdaq: GV) provides access to the company’s U.S. regulatory disclosures, including its annual reports on Form 20-F and current reports on Form 6-K when filed. Visionary Holdings has described itself as a technology-driven multinational enterprise focused on innovative education, AI applications, and high-tech healthcare solutions, with a strategic emphasis on health management, anti-aging medical aesthetics, and regenerative medicine.
In its public communication about the fiscal year ended March 31, 2025, the company referenced its Annual Report on Form 20-F, which outlines strategic transformation, business restructuring progress, and segment information covering real estate leasing, education services, and life sciences and health-related businesses. While specific filings are not reproduced here, investors typically look to Form 20-F for details on business segments, risk factors, financial statements, and management’s discussion of operations.
Visionary Holdings has also mentioned furnishing a Report on Form 6-K in connection with governance updates, including board changes and its formal strategic shift toward anti-aging high-end medical aesthetics. Such filings can provide additional context on corporate actions, partnerships, and compliance matters beyond the annual report.
Through this page on Stock Titan, users can monitor new GV filings as they are made available through the SEC’s EDGAR system. AI-powered tools can help summarize lengthy documents such as Form 20-F, highlighting key points related to Visionary Holdings’ health management initiatives, medical aesthetics partnerships, regenerative medicine licensing arrangements, and AI-enabled education operations. Users can also review shorter filings, such as Form 6-K, to follow governance developments and other material updates disclosed by the company.
Visionary Holdings Inc. reports the results of its 2025 annual shareholder and board meetings and outlines a major strategic shift. Shareholders elected a nine-member fourth Board of Directors and reappointed Assentsure PAC as auditor through the 2025–2026 fiscal year. The new board then chose William T. Chai as chairman and filled other key board roles, formed four committees, and appointed a senior management team including CEO Xiyong Hou, Co-CEO Jun Huang, COO Robert Jay Lees, and CFO Katy Liu.
The company states it has completed a strategic transformation to focus on high-end anti-aging medical aesthetics as its core business, with education as a supplement and AI as a key enabler. It plans AI-driven initiatives in medical aesthetics and education, a professional financial services platform in Hong Kong, and cooperation with two Chinese medical technology companies to develop products globally and build an anti-aging and health center in Toronto. Management cautions that forward-looking statements are subject to policy, market, and cooperation risks.
Visionary Holdings Inc. files its annual report for the year ended March 31, 2025, highlighting a severe downturn in its legacy businesses and a major strategic pivot. Tuition revenue fell versus the prior year, while real estate income declined by 50%, driving an overall 2025 revenue drop of 50% and exposing the impact of tighter Canadian international education policies and a weak real estate market.
To respond, the company is shifting from education and real estate into life sciences, including large health and elderly care, anti‑aging and high‑end medical aesthetics, and AI‑driven education services. Management reports over $1 million in life sciences revenue in the year, about 20% of total revenue, and forecasts that this segment could reach tens of millions of Canadian dollars and more than 80% of revenue next year. However, the company discloses multiple material weaknesses in internal control over financial reporting, approximately $1.28 million in accrued unpaid income tax liabilities to be repaid in installments beginning January 1, 2026, significant dependence on new financing, and concentrated voting control held through super‑voting stock, all of which present meaningful operational and governance risks.